The authors challenged the system with a variant of IL-2, a bispecific antibody that binds to carcinoembryonic antigen (CEA, an antigen overexpressed on different tumour cells) and to CD3 (T lymphocytes), and the combination of these. This evidence concerns the gene CEACAM5 and neoplasm.